The Ewing Family of Tumors Relies on BCL-2 and BCL-X

Animals Antineoplastic Agents / pharmacology Apoptosis / drug effects Cell Death / drug effects Cell Line, Tumor DNA Damage / drug effects Disease Models, Animal Drug Resistance, Neoplasm / genetics Humans Mice Phthalazines / pharmacology Piperazines / pharmacology Poly(ADP-ribose) Polymerase Inhibitors / pharmacology Proto-Oncogene Proteins c-bcl-2 / genetics Sarcoma, Ewing / drug therapy Xenograft Model Antitumor Assays bcl-X Protein / genetics

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 25 01 2018
revised: 11 07 2018
accepted: 17 10 2018
pubmed: 24 10 2018
medline: 9 4 2020
entrez: 24 10 2018
Statut: ppublish

Résumé

It was recently demonstrated that the We employed a pair of cell lines derived from the same patient with Ewing sarcoma prior to and following chemotherapy, a panel of Ewing sarcoma cell lines, and several patient-derived xenograft (PDX) and cell line xenograft models. We found olaparib sensitivity was diminished following chemotherapy. The matched cell line pair revealed increased expression of the antiapoptotic protein BCL-2 in the chemotherapy-resistant cells, conferring apoptotic resistance to olaparib. Resistance to olaparib was maintained in this chemotherapy-resistant model These data reveal BCL-2 and BCL-X

Identifiants

DOI: 10.1158/1078-0432.CCR-18-0277 PMID: 30348635
pubmed: 30348635
pii: 1078-0432.CCR-18-0277
doi: 10.1158/1078-0432.CCR-18-0277
doi:

Substances chimiques

Antineoplastic Agents 0
BCL2 protein, human 0
Phthalazines 0
Piperazines 0
Poly(ADP-ribose) Polymerase Inhibitors 0
Proto-Oncogene Proteins c-bcl-2 0
bcl-X Protein 0
olaparib WOH1JD9AR8

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1664-1675

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016059
Pays : United States

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Daniel A R Heisey (DAR)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Timothy L Lochmann (TL)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Konstantinos V Floros (KV)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Colin M Coon (CM)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Krista M Powell (KM)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Sheeba Jacob (S)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Marissa L Calbert (ML)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Maninderjit S Ghotra (MS)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia.

Giovanna T Stein (GT)

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Yuki Kato Maves (YK)

Crown Bioscience Inc., San Diego, California.

Steven C Smith (SC)

Division of Anatomic Pathology, Virginia Commonwealth University, Richmond, Virginia.
ORCID: 0000-0003-0982-4607

Cyril H Benes (CH)

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
ORCID: 0000-0002-8751-9707

Joel D Leverson (JD)

AbbVie, North Chicago, Illinois.

Andrew J Souers (AJ)

AbbVie, North Chicago, Illinois.

Sosipatros A Boikos (SA)

Hematology, Oncology and Palliative Care, School of Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.

Anthony C Faber (AC)

VCU Philips Institute, School of Dentistry and Massey Cancer Center; Richmond, Virginia. acfaber@vcu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridazines › Phtalazines › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de poly(ADP-ribose) polymérases › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu conjonctif et des tissus mous › Sarcomes › Ostéosarcome › Sarcome d'Ewing › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › The Ewing Family of Tumors Relies on BCL-2 and BCL-X
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines régulatrices de l'apoptose › Protéine bcl-X › The Ewing Family of Tumors Relies on BCL-2 and BCL-X